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CLINICAL CASE
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Abstract  We  report  a  rare  case  of  neuroendocrine  tumor  of  the  anal  canal  and  its  poor  prog-
nosis, plus  discuss  the  need  of  immunohistochemical  for  an  acurate  diagnosis  and  to  guide
treatment.
© 2011  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Resumo  Relatamos  um  caso  raro  de  tumor  neuroendócrino  do  canal  anal  e  seu  mau  prognós-
tico, bem  como  a  necessidade  de  imuno-histoquímica  para  o  diagnóstico  correto  e  para  orientar
sa  de
c
lImunohistoquímica;
Doenc¸a  metastática
o tratamento.
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IntroductionThe  anal  canal  tumors  are  unusual  lesions  whose  frequence
is  about  1.5%  of  the  gastrointestinal  tract  neoplasias.1
The  predominant  histological  type  is  the  squamous  cells
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ancer  (SCC)  (47%),  followed  by  cloacogenic  carcinoma  and
ess  commonly  melanoma  or  mucinous  adenocarcinoma.2 In
elation  to  the  neuroendocrine  tumor  (NET)  occurrence  on
his  location,  its  undeniable  rarity  justiﬁes  this  case  report.ase description
 49-year-old  woman  presented  with  anal  bleeding,  small-
aliber  stool  with  purulent  discharge  and  severe  proctalgia
logia. Published by Elsevier España, S.L. All rights reserved.
268  
SCC squamous  cells  cancer
NET  neuroendocrine  tumor
CK  citokeratin
CgA  cromogranin  A
i
b
l
o
a
h
t
p
p
t
c
t
w
(
e
a
w
m
f
a
t
t
c
a
w
e
ﬁ
l
d
c
w
a
F
2
H
sNSE  neuron-speciﬁc  enolase
n  the  last  three  months.  She  had  no  abominal  pain,  no
owel  habit  changes,  no  fever,  no  loss  weight  and  no  inguinal
ymphadenopathy.  Investigation  was  conducted  by  the  Col-
rectal  Service  of  Hospital  de  Base,  São  José  do  Rio  Preto,
nd  started  in  August  2007.  Two  perianal  condylomas  and  a
ard  anal  mass  were  detected  in  the  rectal  exam  and
he  pathological  evaluation  revealed  condylomatosis  and  a
oorly  differentiated,  ulcerated  and  invasive  SCC.  The
atient  was  treated  with  Nigro.
An  incisional  biopsy  of  the  residual  lesion  was  performed
hat  resulted  in  no  sign  of  malignancy.  One  year  later,
olonoscopy  was  normal  and  there  were  no  metastasis  in
he  imaging  follow-up.  After  7  months,  the  patient  returned
ith  5  cm  bilateral  mammary  and  axillary  protuberances
Fig.  1),  right  inguinal  lymphadenopathy  (Fig.  2)  and  ipsilat-
a
a
i
c
igures  1--8  Axillary  protuberance  (Fig.  1),  inguinal  lymphadenop
 years  after  the  treatment  with  Nigro.  Infected  perianal  metastases
istology revealed  a  poorly  differentiated  SCC  (Fig.  5)  and  immuno
howing positive  neoplastic  cells  for  CK35  (Fig.  6),  CgA  (Fig.  7)  and  A.  Borgonovi  Christiano  et  al.
ral  thigh  abscess  (Fig.  3).  In  face  of  the  possibility  of  canal
nal  tumor  recurrence,  it  was  sought  colonoscopy  and  biopsy
ith  immunohistochemical  markers  search  in  the  potentially
etastatic  lesions.  Neoplastic  cells  were  immunoreactive
or  cytokeratin  (CK)  35  (Fig.  6),  cromogranin  A  (CgA)  (Fig.  7)
nd  neuron-speciﬁc  enolase  (NSE)  (Fig.  8)  that  were  compa-
ible  with  metastatic  high  grade  NET.  The  lamina  revision  of
he  primary  anal  lesion  revealed  poorly  differentiated  car-
inoma  (Fig.  5)  in  ﬁbroconjunctive  tissue  with  necrosis  and
ngiolymphatic  tumor  embolization  areas.
During  the  introduction  of  palliative  chemotherapy
ith  cisplatin  and  irinotecam,  the  patient  developed
nlargement  of  inguinal  lymph  nodes  with  abscesses  and
stulization  in  addiction  to  Fournier  syndrome.  One  month
ater,  infected  perianal  metastases  (Fig.  4)  could  be
etected  associated  with  recurrence  of  Fournier  syndrome,
ontiguity  intravaginal  injury  and  septic  shock  treated
ith  consecutive  debridement,  extended  antibiotic  ther-
py  and  estomal  confection.  Intraoperative  ﬁndings  included metastatic  mass  in  the  greater  omentum.  Chemother-
py  was  discontinued  because  her  immune  status  was
mpaired.  Unfortunately  she  died  in  May  2009  from  septic
omplications.
athy  (Fig.  2)  and  right  thigh  abscess  (Fig.  3)  appearance  almost
 (Fig.  4)  could  be  detected  during  the  palliative  chemotherapy.
histochemical  staining  was  compatible  with  high  grade  NET  by
NSE  (Fig.  8).
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rasco M. Neuroendocrine carcinomas of the colon and rectum.Neuroendocrine  tumor  of  the  anal  canal  
Discussion
NET  can  originate  in  any  part  of  the  body,  for  example,
lungs,  skin,  urogenital  system,  digestive  tract,  thyroid  and
adrenal.3 When  situated  in  large  intestine  (about  0.3-3.9%
of  all  colorrectal  tumors),  they  are  histologically  heteroge-
neous  but  share  high  aggressiveness4 being  more  common
in  caecum,  rectum  and  sigmoid.  Anal  location  is  rare  and
indicates  a  poor  prognosis.5,6 There  is  a  variety  of  NET,
rare  and  aggressive,  with  multidirectional  differentiation,
where  are  observed  foci  of  this  histological  type,  adenocar-
cinoma  and  SCC.7 The  clinical  presentation  of  NET  does  not
differ  from  colorrectal  adenocarcinomas.  However  a  more
advanced  tumor  stage  can  be  observed  at  the  time  of  its
diagnosis.  Rarely  there  are  manifestations  of  paraneoplas-
tic  syndrome,  carcinoid  (diarrhea  and  rash)  and  metabolic
abnormalities.8
It  was  observed  that  the  differentiation  of  an  epithelial
tumor  into  NET  is  an  independent  unfavorable  prognostic
factor.9 For  example,  in  relation  to  colorectal  neoplasias,
Thomas  and  Sobin  (1995)  found  a  27%  survival  at  5  years
for  stages  III  and  IV  adenocarcinoma,  but  only  three  of
51  patients  with  the  same  staging  and  neuroendocrine  dif-
ferentiation  remained  alive  for  two  years  in  that  study.10
Speciﬁc  markers  that  may  be  used  to  establish  neu-
roendocrine  differentiation  comprise  NSE,  CD56,  CgA  and
synaptophysin,  being  the  two  latter  recommended  due
to  their  relative  sensitivity  and  speciﬁcity.11 Immunohisto-
chemical  study  is  also  critical  to  guide  treatment,  as  Nigro
is  used  for  anal  canal  SCC,  while  surgical  removal  remains
the  best  chance  of  cure  for  patients  with  NET.
Only  early  detection  of  the  disease  can  result  in  some
beneﬁt  on  its  evolution  because  adjuvant  interventions  such
as  radio  and  chemotherapy  do  not  constitute  an  impact  fac-
tor  to  improve  survival  in  these  cases.  However  new  lines  of
chemotherapy  are  being  developed  using  streptozotocin  and
5-ﬂuorouracil  or  doxorubicin  with  5-ﬂuorouracil.12 Also  pal-
liative  options  such  as  surgery,  manufacture  of  colostomy
and  radiotherapy  should  be  evaluated  to  improve  the  life
quality  of  patients  with  advanced  disease.Conﬂicts of interest
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